Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

NCT05065970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin A (IgA) Nephropathy

Interventions

DRUG: Felzartamab
OTHER: Placebo

Sponsor

HI-Bio, A Biogen Company